First-of-its-kind head-to-head clinical trial reaffirms the efficacy of Emgality in episodic migraine prevention – Eli Lilly
Eli Lilly and Company announced results of the CHALLENGE-MIG clinical trial of Emgality (galcanezumab-gnlm) and Nurtec ODT (rimegepant orally disintegrating tablet), the first and only trial of its… read more.
